| Market Cap | 294.22M | P/E | - | EPS this Y | 24.00% | Ern Qtrly Grth | - |
| Income | -126.61M | Forward P/E | -2.25 | EPS next Y | 12.80% | 50D Avg Chg | -9.00% |
| Sales | 5.9M | PEG | - | EPS past 5Y | - | 200D Avg Chg | -9.00% |
| Dividend | N/A | Price/Book | 1.05 | EPS next 5Y | - | 52W High Chg | -49.00% |
| Recommedations | 2.10 | Quick Ratio | 6.73 | Shares Outstanding | 66.48M | 52W Low Chg | 42.00% |
| Insider Own | 14.49% | ROA | -23.06% | Shares Float | 48.52M | Beta | 2.79 |
| Inst Own | 79.95% | ROE | -52.14% | Shares Shorted/Prior | 1.58M/1.27M | Price | 4.48 |
| Gross Margin | - | Profit Margin | - | Avg. Volume | 173,675 | Target Price | 7.50 |
| Oper. Margin | -1,334.99% | Earnings Date | May 8 | Volume | 114,943 | Change | -5.49% |
Generation Bio Co. develops non-viral genetic medicines for the treatment of rare and prevalent diseases. The company develops cell-targeted lipid nanoparticle (ctLNP) platform, a modular delivery system for nucleic acids to avoid off-target clearance by the liver and spleen that enables ctLNPs to persist in systemic circulation, which allows for highly selective and potent ligand-driven targeting to specific tissues and cell types; and novel immune-quiet DNA (iqDNA) to enable long-lasting high levels of gene expression from non-integrating episomes and avoids innate immune sensors that have long prevented DNA from use in non-viral systems. It uses its platform for developing a portfolio of programs for treating cancer, autoimmune, hematologic disorders, prioritizing sickle cell, beta-thalassemia, and hemophilia A diseases, as well as for other tissues and cell types, including retina, skeletal muscle, and central nervous system. The company was formerly known as Torus Therapeutics, Inc. and changed its name to Generation Bio Co. in November 2017. Generation Bio Co. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.
| Needham | Buy | Apr 10, 24 |
| Wedbush | Outperform | Mar 7, 24 |
| Needham | Buy | Mar 7, 24 |
| Wedbush | Outperform | Nov 10, 23 |
| JMP Securities | Market Perform | Oct 23, 23 |
| TD Cowen | Market Perform | Oct 19, 23 |
| JP Morgan | Neutral | Aug 16, 23 |
| Needham | Buy | Aug 3, 23 |
| Wedbush | Outperform | Aug 3, 23 |
| Insider Trades | Relationship | Date | Transactions | Cost($) | #Shares | Value($) | #Share Own | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| Appelhans Dannielle | Director Director | Dec 04 | Buy | 1.50 | 12,000 | 18,000 | 12,000 | 12/06/23 |
| Paone Antoinette | CHIEF OPERATING OFFI.. CHIEF OPERATING OFFICER | Aug 23 | Sell | 4.93 | 3,116 | 15,362 | 2,914 | 08/25/23 |
| Samayoa Phillip | CHIEF STRATEGY OFFIC.. CHIEF STRATEGY OFFICER | Jan 09 | Sell | 5.11 | 1,865 | 9,530 | 95,819 | 01/10/23 |
| Paone Antoinette | CHIEF OPERATING OFFI.. CHIEF OPERATING OFFICER | Oct 27 | Sell | 5.03 | 2,914 | 14,657 | 10/28/22 | |
| Paone Antoinette | CHIEF OPERATING OFFI.. CHIEF OPERATING OFFICER | Sep 29 | Sell | 5.24 | 2,828 | 14,819 | 09/30/22 | |
| Rowland Charles A Jr | Director Director | Sep 13 | Buy | 5.25 | 24,384 | 128,016 | 125,419 | 09/15/22 |
| Nicholson Donald William | Director Director | Mar 09 | Buy | 4.75 | 10,419 | 49,490 | 113,576 | 03/11/22 |
| Rhodes Jason P | Director Director | Jun 23 | Sell | 25.11 | 185,078 | 4,647,309 | 666 | 06/23/21 |
| Rhodes Jason P | Director Director | Apr 14 | Sell | 26.08 | 140,682 | 3,668,987 | 04/14/21 | |
| - | - - | Apr 14 | Sell | 26.08 | 140,682 | 3,668,987 | 04/14/21 | |
| - | - - | Apr 09 | Sell | 28.49 | 127,095 | 3,620,937 | 140,682 | 04/09/21 |
| Rhodes Jason P | Director Director | Apr 09 | Sell | 28.49 | 127,095 | 3,620,937 | 140,682 | 04/09/21 |
| Zimmermann Tracy | CHIEF DEVELOPMENT OF.. CHIEF DEVELOPMENT OFFICER | Jan 15 | Option | 4.59 | 2,500 | 11,475 | 2,500 | 01/15/21 |
| Zimmermann Tracy | CHIEF DEVELOPMENT OF.. CHIEF DEVELOPMENT OFFICER | Jan 15 | Sell | 33.09 | 2,500 | 82,725 | 01/15/21 | |
| Stanton Matthew | CHIEF SCIENTIFIC OFF.. CHIEF SCIENTIFIC OFFICER | Jan 15 | Option | 0.6 | 5,630 | 3,378 | 203,784 | 01/15/21 |
| Stanton Matthew | CHIEF SCIENTIFIC OFF.. CHIEF SCIENTIFIC OFFICER | Jan 15 | Sell | 32.56 | 5,630 | 183,313 | 198,154 | 01/15/21 |
| Kerr Douglas | CHIEF MEDICAL OFFICE.. CHIEF MEDICAL OFFICER | Jan 13 | Option | 4.59 | 11,267 | 51,716 | 337,825 | 01/13/21 |
| Kerr Douglas | CHIEF MEDICAL OFFICE.. CHIEF MEDICAL OFFICER | Jan 13 | Sell | 28.01 | 11,267 | 315,589 | 326,558 | 01/13/21 |
| Stanton Matthew | CHIEF SCIENTIFIC OFF.. CHIEF SCIENTIFIC OFFICER | Jan 13 | Option | 0.6 | 14,820 | 8,892 | 212,974 | 01/13/21 |
| Stanton Matthew | CHIEF SCIENTIFIC OFF.. CHIEF SCIENTIFIC OFFICER | Jan 13 | Sell | 27.99 | 14,820 | 414,812 | 198,154 | 01/13/21 |
| Stanton Matthew | Chief Scientific Off.. Chief Scientific Officer | Dec 14 | Option | 0.6 | 10,540 | 6,324 | 208,694 | 12/14/20 |